We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+1.54%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$79.7M
AUM Growth
-$662M
(-89%)
Cap. Flow
-$660M
Cap. Flow
% of AUM
-828.28%
Top 10 Holdings %
Top 10 Hldgs %
21.47%
Holding
303
New
144
Increased
52
Reduced
48
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.36M |
| 2 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$1.1M |
| 3 |
ProShares Ultra Utilities
UPW
|
+$905K |
| 4 |
Lexicon Pharmaceuticals
LXRX
|
+$786K |
| 5 |
Puma Biotechnology
PBYI
|
+$617K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ETP
Energy Transfer Partners, L.P.
ETP
|
+$93.5M |
| 2 |
WPZ
Williams Partners L.P.
WPZ
|
+$65M |
| 3 |
BPL
Buckeye Partners, L.P.
BPL
|
+$48.9M |
| 4 |
Energy Transfer Partners
ET
|
+$45.2M |
| 5 |
Enterprise Products Partners
EPD
|
+$40.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.8% |
| 2 | Financials | 1.05% |
| 3 | Consumer Discretionary | 0.59% |
| 4 | Technology | 0.58% |
| 5 | Consumer Staples | 0.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Theravance Biopharma
TBPH
$874M
| $974K | 1.22% |
34,929
+7,283
| +26% | +$216K |
|
27
BioMarin Pharmaceuticals
BMRN
$11.4B
| $973K | 1.22% |
10,910
-350
| -3% | -$30.4K |
|
28
Omeros
OMER
$744M
| $973K | 1.22% |
50,065
+2,953
| +6% | +$55.4K |
|
29
Incyte
INCY
$23.3B
| $967K | 1.21% |
10,205
+1,586
| +18% | +$166K |
|
|
MDCO
30
DELISTED
Medicines Co
MDCO
| $963K | 1.21% |
35,217
+8,157
| +30% | +$251K |
|
|
31
Puma Biotechnology
PBYI
$408M
| $955K | 1.2% |
9,661
+5,514
| +133% | +$617K |
|
32
Biogen
BIIB
$29.6B
| $953K | 1.2% |
2,990
-1,095
| -27% | -$351K |
|
33
Gilead Sciences
GILD
$162B
| $952K | 1.19% |
13,288
-2,638
| -17% | -$200K |
|
34
Regeneron Pharmaceuticals
REGN
$68.3B
| $950K | 1.19% |
2,526
+355
| +16% | +$144K |
|
|
DVAX
35
DELISTED
Dynavax Technologies
DVAX
| $949K | 1.19% |
50,726
+19,405
| +62% | +$390K |
|
|
36
Lexicon Pharmaceuticals
LXRX
$1.02B
| $939K | 1.18% |
95,079
+75,607
| +388% | +$786K |
|
37
Ironwood Pharmaceuticals
IRWD
$624M
| $937K | 1.18% |
74,625
+4,960
| +7% | +$64.8K |
|
38
Ionis Pharmaceuticals
IONS
$9.23B
| $936K | 1.17% |
18,610
-1,765
| -9% | -$96.8K |
|
39
Travere Therapeutics
TVTX
$5.27B
| $933K | 1.17% |
44,297
-12,356
| -22% | -$282K |
|
|
CELG
40
DELISTED
Celgene Corp
CELG
| $919K | 1.15% |
8,805
+254
| +3% | +$28.7K |
|
|
ICPT
41
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $908K | 1.14% |
15,542
+7,041
| +83% | +$444K |
|
42
Vanguard Real Estate ETF
VNQ
$39.1B
| $702K | 0.88% |
8,461
+750
| +10% | +$62.9K |
|
|
RXDX
43
DELISTED
Ignyta, Inc.
RXDX
| $612K | 0.77% |
22,936
-15,420
| -40% | -$250K |
|
|
LJPC
44
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $463K | 0.58% |
14,394
+2,549
| +22% | +$83.3K |
|
|
IMMU
45
DELISTED
Immunomedics Inc
IMMU
| $456K | 0.57% |
28,196
-14,588
| -34% | -$172K |
|
|
PVLA
46
Palvella Therapeutics
PVLA
$2.05B
| $432K | 0.54% |
+715
| New | +$332K |
|
47
iShares MSCI India ETF
INDA
$6.65B
| $427K | 0.54% |
+11,844
| New | +$412K |
|
|
XLRN
48
DELISTED
Acceleron Pharma
XLRN
| $414K | 0.52% |
9,748
-1,229
| -11% | -$46.1K |
|
|
ARRY
49
DELISTED
Array Biopharma Inc
ARRY
| $411K | 0.52% |
32,118
-10,118
| -24% | -$115K |
|
50
Regenxbio
RGNX
$656M
| $407K | 0.51% |
12,251
-5,020
| -29% | -$151K |
|
Similar funds
NCM
OC
SSA
LIWM
VFG
IAM
1M
GC
Virtus ETF Advisers's Q4 2017 Portfolio in Review
As of Q4 2017, Virtus ETF Advisers held 303 positions worth $79.7M, down 89% from $742M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Virtus ETF Advisers withdrew a net $660M in Q4 2017, closing 59 positions and reducing 48 holdings. Its most notable exit was Energy Transfer Partners, L.P., an estimated $93.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 7.9% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Virtus ETF Advisers opened a new position in iShares MSCI India ETF worth $427K.
- Virtus ETF Advisers's largest Q4 2017 buy was iShares MSCI India ETF: 11,844 shares worth $427K.
- Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q4 2017, an estimated $1.36M increase.
- Virtus ETF Advisers's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $1.55M.
- Virtus ETF Advisers fully exited Energy Transfer Partners, L.P. in Q4 2017, selling an estimated $93.5M.
- Virtus ETF Advisers's ten largest holdings make up 21% of its $79.7M portfolio in Q4 2017.
- Virtus ETF Advisers opened 144 new positions and closed 59 in Q4 2017.
- Virtus ETF Advisers's portfolio value fell 89% quarter-over-quarter to $79.7M.
Based on Virtus ETF Advisers's 13F filing for Q4 2017, filed 14 Feb 2018.